Clinical Journal of Gastroenterology

, Volume 12, Issue 6, pp 578–582 | Cite as

Hyposensitization trial using salazosulfapyridine in a case of mesalamine intolerance

  • Koichi SogaEmail author
  • Kenji Itani
Case Report


A 47-year-old Japanese man was diagnosed with pancolitis-type ulcerative colitis. He was treated with mesalamine in a pH-dependent release form. On day 16 of administration, he was admitted because of fever and abdominal pain. We diagnosed his symptoms to be the side effects of mesalamine. Hyposensitization using unmodified and a time-dependent release form mesalamine was performed. On day 7 of mesalamine hyposensitization, a colonoscopy was performed. The patient presented with the same allergic symptoms 9 h after the administration of an oral sodium phosphate solution. Eventually, he was orally administered a course of salazosulfapyridine (SASP) at an initial dose of 2.5 mg/day, which was increased to 2000 mg/day. It is generally recognized that SASP intolerance is an indication to switch from SASP to mesalamine. The need to switch treatment from mesalamine to SASP is, therefore, rare because allergic reactions to mesalamine do not occur frequently. We report a very rare case which was presented with abdominal pain and myalgia because of intolerance to mesalamine in whom hyposensitization with and introduction of SASP were successful.


Mesalamine Oral sodium phosphate solution Salazosulfapyridine Ulcerative colitis 



Oral sodium phosphate solution






Ulcerative colitis


Compliance with ethical standards

Conflicts of interest

The authors state that they have no conflict of interest.

Human/animal rights

All procedures were performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.

Informed consent

Informed consent was obtained from all the patients for being included in the study.


  1. 1.
    Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazo-sulfapyridine. J Pharmacol Exp Ther. 1972;181:555–62.PubMedGoogle Scholar
  2. 2.
    Sturgeon JB, Bhatia P, Hermens D, et al. Exacerbation of chronic ulcerative colitis with mesalamine. Gastroenterology. 1995;108:1889–93.CrossRefGoogle Scholar
  3. 3.
    Bousseaden A, Ajana FZ, Essamri W, et al. Mesalamine enema-induced exacerbation of ulcerative colitis. Int J Colorectal Dis. 2009;24:1359–60.CrossRefGoogle Scholar
  4. 4.
    Scribano ML. Adverse events of IBD therapies. Inflamm Bowel Dis. 2008;14(Suppl 2):S210–1.CrossRefGoogle Scholar
  5. 5.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N Engl J Med. 1987;317:1625–9.CrossRefGoogle Scholar
  6. 6.
    Geboes K, Riddell R, Ost A, et al. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404–9.CrossRefGoogle Scholar
  7. 7.
    Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol Clin North Am. 1992;21:643–58.PubMedGoogle Scholar
  8. 8.
    Rasmussen SN, Bondesen S, Hvidberg EF, Hansen SH, Binder V, Halskov S, Flachs H. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982;83:1062–70.PubMedGoogle Scholar
  9. 9.
    Karagozian R, Burakoff R. The role of mesalamine in the treatment of ulcerative colitis. Ther Clin Risk Manag. 2007;3:893–903.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Rubin DT, Mikolajczyk A, Surma B. Measurement of luminal pH in patients with mildly to moderately active UC: a pilot study using SMARTpill pH. Gastroenterology. 2009;135:A349.Google Scholar
  11. 11.
    Menees S, Higgins P, Korsnes S, Elta G. Does colonoscopy cause increased ulcerative colitis symptoms? Inflamm Bowel Dis. 2007;13:12–8.CrossRefGoogle Scholar
  12. 12.
    Schleiermacher D, Hoffmann JC. Pulmonary abnormalities in inflammatory bowel disease. J Crohns Colitis. 2007;1:61–9.CrossRefGoogle Scholar
  13. 13.
    Hautekeete ML, Bourgeois N, Potvin P, et al. Hypersensitivity with hepatotoxicity to mesalazine after hypersensitivity to sulfasalazine. Gastroenterology. 1992;103:1925–7.CrossRefGoogle Scholar
  14. 14.
    Fardy JM, Lloyd DA, Reynolds RPE. Adverse effects with oral 5-aminosalicylic acid. J Clin Gastroenterol. 1988;10:635–7.CrossRefGoogle Scholar
  15. 15.
    Gonzalo MA, Alcalde MM, García JM, et al. Desensitization after fever induced by mesalazine. Allergy. 1999;54:1224–5.CrossRefGoogle Scholar
  16. 16.
    Varela S, Díez MS, Gonzalez C, et al. Oral desensitization to 5-ASA. Allergy. 2002;57:371–2.CrossRefGoogle Scholar
  17. 17.
    Oustamanolakis P, Koutroubakis IE. New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance. Inflamm Bowel Dis. 2011;17:E8–9.CrossRefGoogle Scholar
  18. 18.
    Korelitz BI, Present DH, Rubin PH, et al. Desensitization to sulfasalazine after hypersensitivity reactions in patients with inflammatory bowel disease. J Clin Gastroenterol. 1984;6:27–31.CrossRefGoogle Scholar
  19. 19.
    Wang Y, Parker CE, Bhanji T, et al. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;4:CD000543.PubMedGoogle Scholar
  20. 20.
    Wang Y, Parker CE, Feagan BG, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2016;5:000544.Google Scholar

Copyright information

© Japanese Society of Gastroenterology 2019

Authors and Affiliations

  1. 1.Department of Internal MedicineNishijin HospitalKyotoJapan
  2. 2.Department of GastroenterologyOmihachiman Community Medical CenterOmihachimanJapan

Personalised recommendations